Kiora Pharmaceuticals (KPRX) Competitors

Kiora Pharmaceuticals logo
$0.72 -0.10 (-12.28%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.73 +0.01 (+0.81%)
As of 11/20/2026 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KPRX vs. ZIVO, FLNA, CPHI, VIRI, and TAOX

Should you buy Kiora Pharmaceuticals stock or one of its competitors? Kiora Pharmaceuticals's main competitors and comparable companies include ZIVO Bioscience (ZIVO), Cassava Sciences (FLNA), China Pharma (CPHI), Virios Therapeutics (VIRI), and Synaptogenix (TAOX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Kiora Pharmaceuticals compare to ZIVO Bioscience?

Kiora Pharmaceuticals (NASDAQ:KPRX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

ZIVO Bioscience's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiora PharmaceuticalsN/A -82.06% -55.72%
ZIVO Bioscience N/A N/A -2,240.92%

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiora Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company Overall Sentiment
Kiora Pharmaceuticals Neutral
ZIVO Bioscience Neutral

Kiora Pharmaceuticals has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

ZIVO Bioscience has lower revenue, but higher earnings than Kiora Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiora Pharmaceuticals$16.02M0.20-$10.84M-$2.80N/A
ZIVO Bioscience$15.85K1,462.62-$7.78M-$1.19N/A

Summary

ZIVO Bioscience beats Kiora Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cassava Sciences has a beta of -0.48, indicating that its stock price is 148% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market.

Kiora Pharmaceuticals has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$0.87N/A
Kiora Pharmaceuticals$16.02M0.20-$10.84M-$2.80N/A

Cassava Sciences' return on equity of -63.91% beat Kiora Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -63.91% -39.19%
Kiora Pharmaceuticals N/A -82.06%-55.72%

In the previous week, Cassava Sciences had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Cassava Sciences and 0 mentions for Kiora Pharmaceuticals. Cassava Sciences' average media sentiment score of 1.30 beat Kiora Pharmaceuticals' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Cassava Sciences Positive
Kiora Pharmaceuticals Neutral

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 681.25%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Kiora Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Kiora Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Cassava Sciences beats Kiora Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to China Pharma?

Kiora Pharmaceuticals (NASDAQ:KPRX) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiora Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
China Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Kiora Pharmaceuticals has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, China Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

China Pharma has lower revenue, but higher earnings than Kiora Pharmaceuticals. China Pharma is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiora Pharmaceuticals$16.02M0.20-$10.84M-$2.80N/A
China Pharma$3.91M4.82-$3.08M-$0.30N/A

Kiora Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Kiora Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiora PharmaceuticalsN/A -82.06% -55.72%
China Pharma -85.56%-63.93%-31.42%

In the previous week, China Pharma had 2 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for China Pharma and 0 mentions for Kiora Pharmaceuticals. China Pharma's average media sentiment score of 0.04 beat Kiora Pharmaceuticals' score of 0.00 indicating that China Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Kiora Pharmaceuticals Neutral
China Pharma Neutral

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 29.5% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

China Pharma beats Kiora Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Kiora Pharmaceuticals' return on equity of -82.06% beat Virios Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Virios TherapeuticsN/A -130.33% -115.00%
Kiora Pharmaceuticals N/A -82.06%-55.72%

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Virios Therapeutics Neutral
Kiora Pharmaceuticals Neutral

Virios Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Virios Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A
Kiora Pharmaceuticals$16.02M0.20-$10.84M-$2.80N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Kiora Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

Summary

Kiora Pharmaceuticals beats Virios Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kiora Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -768.22%. Synaptogenix's return on equity of -68.89% beat Kiora Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Synaptogenix-768.22% -68.89% -49.33%
Kiora Pharmaceuticals N/A -82.06%-55.72%

Synaptogenix has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

In the previous week, Synaptogenix had 2 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for Synaptogenix and 0 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 beat Synaptogenix's score of -0.65 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Synaptogenix Negative
Kiora Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Kiora Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Kiora Pharmaceuticals has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synaptogenix$300K41.54-$28.74M-$3.85N/A
Kiora Pharmaceuticals$16.02M0.20-$10.84M-$2.80N/A

Summary

Kiora Pharmaceuticals beats Synaptogenix on 7 of the 13 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPRX vs. The Competition

MetricKiora PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.19M$13.12B$7.44B$10.86B
Dividend YieldN/A2.62%2.51%4.60%
P/E Ratio-0.2627.8232.5628.65
Price / SalesN/A7.297.765.15
Price / CashN/A15.2220.2520.77
Price / Book0.215.164.343.51
Net Income-$10.84M$2.86B$3.51B$394.12M
7 Day Performance-41.45%-7.27%-8.07%-8.97%
1 Month Performance-69.22%-9.60%-10.29%-11.61%
1 Year Performance-61.49%-9.28%-4.70%-11.21%

Kiora Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPRX
Kiora Pharmaceuticals
0.3311 of 5 stars
$0.72
-12.3%
N/A-61.5%$3.19MN/AN/A13
ZIVO
ZIVO Bioscience
N/A$5.76
flat
N/A-31.3%$24.28M$15.85KN/A10
FLNA
Cassava Sciences
2.6987 of 5 stars
$0.48
0.0%
$5.00
+937.1%
-77.7%$24.25MN/AN/A30
CPHI
China Pharma
N/A$0.54
-1.4%
N/A-72.6%$23.71M$3.91MN/A215
VIRI
Virios Therapeutics
N/A$1.23
+2.5%
N/A-82.6%$23.69MN/AN/A5

Related Companies and Tools


This page (NASDAQ:KPRX) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners